Samsara Biocapital, LLC
Samsara Biocapital, LLC reported 24 US-listed holdings worth $1.22 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Scholar Rock Holding Corporation (31.2%), Alumis Inc. (14.7%) and Mineralys Therapeutics Inc. (13.0%). Against the quarter before, it opened 4 positions, added to 2, trimmed 5 and sold out of 2.
Filed before as Samsara BioCapital, LLC.
Reported holdings$1.22B+18.3% on Q1 2026
Positions24+2 on Q1 2026
The largest ten90.5%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
OpenedAdded toHeldTrimmed
The 14 largest of its 24 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Opened 4Added 2Held 13Trimmed 5Sold out 2
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 4
- Alamar Biosciences Inc. ALMR$67.2 million
- Parabilis Medicines Inc. Com PBLS$15.2 million
- Artiva Biotherapeutics Inc. ARTV$9.3 million
- Eloxx Pharmaceuticals Inc. ELOX$5.6 million
Added to 2
- Inventiva SA IVA+1.1 million shares · +22%
- Rani Therapeutics Holdings-A RANI+1.9 million shares · +22%
Trimmed 5
- Jade Biosciences Inc. JBIO-232,561 shares · -24%
- Upstream Bio Inc. UPB-382,330 shares · -52%
- X4 Pharmaceuticals Inc. XFOR-436,979 shares · -24%
- Kalaris Therapeutics Inc KLRS-66,906 shares · -1%
- Abivax SA ABVX-1,486 shares · -3%
Sold out of 2
- Arcellx Inc. ACLX$7.0 million last quarter
- Palvella Therapeutics Inc. Ne PVLA$4.8 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Scholar Rock Holding Corporation SRRK | 6,897,652 | $379.4 million | 31.16% | no change |
| Alumis Inc. ALMS | 6,345,219 | $178.6 million | 14.67% | no change |
| Mineralys Therapeutics Inc. MLYS | 5,871,018 | $158.4 million | 13.01% | no change |
| Septerna Inc. SEPN | 3,149,128 | $105.5 million | 8.66% | no change |
| Alamar Biosciences Inc. ALMR | 2,480,310 | $67.2 million | 5.52% | new |
| Neurogene Inc. NGNE | 1,717,127 | $54.0 million | 4.44% | no change |
| Kalaris Therapeutics Inc KLRS | 12,881,175 | $52.4 million | 4.31% | -66,906 |
| Spyglass Pharma Inc. SGP | 2,109,953 | $47.0 million | 3.86% | no change |
| Sutro Biopharma Inc. STRO | 1,062,872 | $35.3 million | 2.90% | no change |
| Inventiva SA IVA | 6,314,805 | $23.9 million | 1.96% | +1,120,000 |
| Jade Biosciences Inc. JBIO | 736,237 | $16.4 million | 1.34% | -232,561 |
| Parabilis Medicines Inc. Com PBLS | 556,044 | $15.2 million | 1.25% | new |
| VTV Therapeutics Inc. Class A New VTVT | 298,496 | $11.2 million | 0.92% | no change |
| Aquestive Therapeutics Inc. AQST | 2,500,000 | $10.4 million | 0.85% | no change |
| Nkarta Inc. NKTX | 3,507,666 | $9.9 million | 0.82% | no change |
| Artiva Biotherapeutics Inc. ARTV | 954,861 | $9.3 million | 0.76% | new |
| Rani Therapeutics Holdings-A RANI | 10,369,159 | $7.9 million | 0.65% | +1,869,159 |
| Agomab Therapeutics NV AGMB | 600,000 | $7.8 million | 0.64% | no change |
| Abivax SA ABVX | 55,095 | $7.3 million | 0.60% | -1,486 |
| X4 Pharmaceuticals Inc. XFOR | 1,395,587 | $6.5 million | 0.54% | -436,979 |
| Eloxx Pharmaceuticals Inc. ELOX | 400,000 | $5.6 million | 0.46% | new |
| Coherus Biosciences Inc. CHRS | 3,428,571 | $4.8 million | 0.39% | no change |
| Upstream Bio Inc. UPB | 353,717 | $2.4 million | 0.20% | -382,330 |
| Gossamer Bio Inc. GOSS | 7,222,559 | $1.2 million | 0.10% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.